Health ❯Healthcare ❯Pharmaceuticals

Drug Regulation

FDA FDA Decisions Compounding Pharmacies Mifepristone Compounded Medications FDA Actions Alzheimer's Disease Access to Medication Alzheimer's Therapy Psychedelic Treatments

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

He steps into the government’s largest drug safety unit at a time of deep workforce reductions under Health Secretary Robert F. Kennedy Jr.

Second Policymakers’ Forum Showcases India’s Role as Global Vaccine Supplier and Regulator

MHRA Recalls Two Batches of Prescription Paracetamol for Potential Contamination

West Bengal Bans 137 Substandard Medicines in Latest Crackdown

Trump Expands Drug Pricing Model to Medicare and Medicaid, Targets Global Parity

HHS Orders FDA Review of Abortion Pill Following Controversial Analysis

Newsom Pushes State Regulation of PBMs and CalRx Expansion in 2025 Budget Plan

Federal Judge Upholds FDA Ban on Compounded Ozempic and Wegovy Copies

India Bans 35 Unapproved Fixed-Dose Combination Drugs

FDA Seizes Counterfeit Ozempic in U.S. Supply Chain

UK Tightens Rules for Online Prescriptions of Weight-Loss Drugs

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

FDA Moves to Ban Ineffective Oral Phenylephrine from Cold Medicines

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

FDA Reconsiders Ban on Compounded Versions of Eli Lilly's Weight Loss Drug

Eli Lilly Fights Back Against Compounded Tirzepatide Amid FDA Supply Resolution

FDA Declares End to Tirzepatide Shortage, Impacting Compounded Drug Market

EU Regulator Denies Approval for Alzheimer's Drug Lecanemab